Effective date: August 2018

Site References

  1. Drukker, C.A., et al. Int. J. Cancer. (Jan 2013) 133: 929–936 (RASTER).
  2. Buyse M. et al. JNCI. (Sept 2006) 98 (17): 11831192. 
  3. Carlson JJ, et al. Breast Cancer Res Treat. (Aug 2013) 141(1): 13–22.
  4. Cusumano PG, et al. The Breast. 2014. doi: 10.1016/j.breast.2014.02.011.
  5. van ‘t Veer et al.  Nature. (Jan 2002) 415, 530-536
  6. McGee et al.  EMBO Reports, (Oct 2006) doi: 10.1038/sj.embor.7400839
  7. Knauer et al. Breast Cancer Res Treat, (Mar 2010) 120(3):655-661.
  8. US FDA 510K Clearance – K101454
  9. Delahaye L et al. Personalized Medicine. (2013) 10(3):801-811
  10. Glück S. et al.  Breast Cancer Res Treat. (June 2013) 139(3):759-767
  11. Cristofanilli M. et al. Cancer Res. 2012;72(24 Suppl):Abstract nr P3-05-01.
  12. Krijgsman O. et al. Breast Cancer Res Treat. (Aug 2012) 133:37-47
  13. Tian, S. et al. Biomarker Insights. (Nov 2010) 5: 129-138
  14. Whitworth P. et al. Annals of Surg. Onc. (Oct 2014) 10:326-7
  15. Roepman P. et al. Clin Cancer Res. (Nov 2009) 15:7003-7011
  16. Oyama T. et al. Breast Cancer. (Apr 2007) 14:1828
  17. Allred DC. The Oncologist. (Nov 2008) 13(11):1134-1136
  18. Viale G. et al. Annals of Oncology. (Apr 2014) 25(4):816-823
  19. Maak M. et al. Annals of Surgery. (Jun 2013) 257(6):1053-1058
  20. Benson AB 3rd et al. J Clin Oncol. (2004) 22:3408–3419
  21. Salazar R. et al. JCO. (Jan 2011) 29(1):17-24 
  22. Tabernero J. et al. J Clin Oncol 30, 2012 (suppl 4; abstr 384)
  23. American Cancer Society. “Tamoxifen and Raloxifene.” Cancer.org. Web. 17 July 2014